These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 24354995

  • 1. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B.
    Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC, Chuang WL, Taiwan NA-Registry Group.
    J Gastroenterol Hepatol; 2014 Jan; 29(1):185-92. PubMed ID: 24354995
    [Abstract] [Full Text] [Related]

  • 2. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [Abstract] [Full Text] [Related]

  • 3. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification.
    Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK.
    Yonsei Med J; 2018 May; 59(3):383-388. PubMed ID: 29611400
    [Abstract] [Full Text] [Related]

  • 4. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
    Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, Hou JL.
    Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):891-5. PubMed ID: 17313873
    [Abstract] [Full Text] [Related]

  • 5. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [Abstract] [Full Text] [Related]

  • 6. Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients.
    Lin YS, Shih SC, Wang HY, Lin CC, Chang CW, Chen MJ.
    BMC Gastroenterol; 2017 Jan 31; 17(1):22. PubMed ID: 28137301
    [Abstract] [Full Text] [Related]

  • 7. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
    Law ST, Lee MK, Lee AS, Tung Y, Li KK.
    J Dig Dis; 2016 May 31; 17(5):325-33. PubMed ID: 27085094
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr 31; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 9. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL, VIRGIL Surveillance Study Group.
    J Hepatol; 2010 Apr 31; 52(4):493-500. PubMed ID: 20185191
    [Abstract] [Full Text] [Related]

  • 10. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    J Gastroenterol Hepatol; 2010 Aug 31; 25(8):1374-80. PubMed ID: 20659226
    [Abstract] [Full Text] [Related]

  • 11. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ, Wang L, Yang BH, Zhao JJ, Liu F, Xue Y, Li T.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr 31; 20(4):280-4. PubMed ID: 22964149
    [Abstract] [Full Text] [Related]

  • 12. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.
    Liu B, Shen B, Mei M, Li L, Wang X, Zhao H.
    Ther Apher Dial; 2020 Feb 31; 24(1):56-63. PubMed ID: 31090170
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up.
    Liao YJ, Li YC, Lee SW, Wu CY, Yang SS, Yeh HZ, Chang CS, Lee TY.
    J Chin Med Assoc; 2017 Dec 31; 80(12):758-765. PubMed ID: 28974354
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.
    J Gastroenterol Hepatol; 2008 Sep 31; 23(9):1320-6. PubMed ID: 18554238
    [Abstract] [Full Text] [Related]

  • 15. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.
    J Antimicrob Chemother; 2012 Mar 31; 67(3):696-9. PubMed ID: 22174039
    [Abstract] [Full Text] [Related]

  • 16. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.
    J Hepatol; 2010 Sep 31; 53(3):449-54. PubMed ID: 20646776
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK, Fontana RJ.
    Aliment Pharmacol Ther; 2012 Mar 31; 35(6):674-89. PubMed ID: 22257108
    [Abstract] [Full Text] [Related]

  • 18. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ.
    Antivir Ther; 2012 Mar 31; 17(1):53-60. PubMed ID: 22267469
    [Abstract] [Full Text] [Related]

  • 19. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.
    Scand J Gastroenterol; 2011 Sep 31; 46(9):1111-7. PubMed ID: 21623676
    [Abstract] [Full Text] [Related]

  • 20. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
    Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH.
    J Gastroenterol Hepatol; 2014 Mar 31; 29(3):568-75. PubMed ID: 24716215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.